FDA says Merck's ridaforolimus meets study goal

WASHINGTON, March 16 (Reuters) - U.S. health regulators on Friday said Merck & Co Inc's ridaforolimus tablets met their primary research end-point of reducing by 25 percent the risk of progression or death in patients with metastatic bone sarcoma.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.